secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2026-07-13T20:25:14+00:00
Accession:  0001746473-26-000107
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics appoints two new independent directors, expands board to nine
--------------------------------------------------------------------------------

- Board size increased from 7 to 9; Robert Iannone, M.D. and Flavia Borellini, Ph.D. appointed as Class I and Class II directors respectively.
- Iannone joins R&D Committee; Borellini appointed chair of R&D Committee.
- Each new director receives annual retainer of $40,000, plus committee fees; each granted option for 60,000 shares vesting over 3 years.
- Both directors determined independent under SEC and Nasdaq rules; no material transactions with company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/0001746473-26-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/plrx-20260709.htm
  HTML page:      https://secwatch.observer/filing/0001746473-26-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer